Sign in
Taking people in NetherlandsPhase 3

Testing ambroxol in people with Gaucher disease type 3

Tests whether ambroxol changes a spinal fluid marker in Gaucher disease type 3.

Key facts

Who runs it
Amsterdam UMC Stichting
Where
Amsterdam, NetherlandsSee the site
Registry title
Effectiveness of ambroxol in children and adults with Gaucher disease 3: n-of-1 series
Status
Recruiting
Phase
Phase 3
People taking part
4 people, planned
Started
25 Nov 2024
Expected to end
1 Sept 2027
Type of study
Interventional
Record updated
25 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and adults with Gaucher disease type 3 who already receive enzyme replacement therapy. It looks at how ambroxol changes a marker in spinal fluid.

Age
All ages, up to 64 Years
Sex
All sexes can join.
Disease stage
Gaucher disease type 3, with documented low GCase enzyme activity and a GBA gene type that fits type 3.
Earlier treatment
Must be on enzyme replacement therapy (ERT), with the treatment ongoing at enrollment. Must not have received an investigational product within 30 days before enrollment.
Biomarker or test result
Documented deficiency of GCase activity and a GBA genotype fitting Gaucher disease type 3.

Main reasons for not taking part

  • Depends on blood transfusions
  • Known allergy or bad reaction to ambroxol or its inactive ingredients
  • Pregnant or breastfeeding
  • Cannot swallow powder and has no other way to take it, such as a gastrostomy
  • Cannot or will not follow the study requirements

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • The patient or the parent(s) / legal guardian(s) must provide written informed consent before start of the study
  • Male and female patients with documented deficiency of GCase activity and GBA genotype fitting GD3
  • Male and female patients of all ages
  • Able to travel to the study site
  • Patients receive ERT with treatment ongoing at the time of enrollment

Who cannot take part

  • The patient has received an investigational product within 30 days prior to enrollment
  • Known hypersensitivity reactions, intolerance or adverse reactions to ambroxol or to the inactive ingredients
  • Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients
  • The patient is transfusion dependent
  • Pregnancy, because there are no sufficient data for the use of ambroxol in pregnant women (see Summary of Product Characteristics (SPC))
  • The patient is lactating. Ambroxol crosses into the breast milk. As there is no adequate experience in humans to date, ambroxol should not be used in lactation in a study setting (see SPC)
  • The patient is unwilling or, in the investigator's opinion, unable to adhere to the requirements of the study
  • The patient is unable to swallow powder and has no other enteral access (e.g. gastrostomy)

Where in Netherlands

  • Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people

About the trial

What the trial wants to find out

Effect of ambroxol on cerebrospinal fluid (CSF) Lyso-GL1 in GD3 patients receiving ambroxol.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Effectiveness of ambroxol in children and adults with Gaucher disease 3: n-of-1 series
Plain-language title
Testing ambroxol in people with Gaucher disease type 3Generated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
25 November 2024